Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates

Table 5 Preclinical (MSR and HR) and clinical (OS and PFS HR) estimates of survival efficacy. LB: lower bound; UB: upper bound

Treatment	Preclinical MSRs			Preclinical HRs			Clinical OS HRs			Clinical PFS HRs
	Estimate	95% CI		Estimate	95% CI		Estimate	95% CI		Estimate	95% CI
		LB	UB		LB	UB		LB	UB		LB	LB
Anti-CTLA-4	0.82	0.78	0.86	0.30	0.17	0.53	0.88	0.76	1.01	0.76	0.54	1.08
Anti-PD-1	0.84	0.80	0.88	0.31	0.18	0.55	0.77	0.73	0.82	0.89	0.79	1.00
Anti-PD-L1	0.83	0.79	0.87	0.30	0.17	0.54	0.86	0.79	0.93	1.04	0.87	1.23
Anti-CTLA-4 + anti-PD-1	0.82	0.75	0.89	0.36	0.20	0.66	0.71	0.62	0.81	0.64	0.45	0.90
Anti-CTLA-4 + anti-PD-L1	0.79	0.67	0.93	0.36	0.20	0.66	0.87	0.74	1.03	1.03	0.73	1.46
Anti-CTLA4 + Chemotherapy	0.80	0.54	1.20	0.31	0.10	0.99	0.87	0.75	1.01	0.86	0.57	1.30
Anti-PD-1 + Chemotherapy	0.63	0.53	0.76	0.17	0.08	0.38	0.73	0.66	0.82	0.69	0.55	0.87
Anti-PD-L1 + Chemotherapy	0.86	0.58	1.25	0.20	0.07	0.60	0.82	0.73	0.91	0.71	0.56	0.88

ISSN: 2396-832X